Sentences with phrase «cell replacement»

This brings together the two leaders in cell replacement therapies for diabetes.

A continuous process of cell replacement goes on in our bodies.

Therefore, numerous research activities address these issues in order to provide beta cell replacement therapy to a broader cohort of patients with diabetes.

The findings may represent a first step toward developing patient - specific cell replacement therapy for type 1 diabetes.

Several clinical trials are testing cell replacement therapies to treat spinal cord injuries.

Similarly, in the laboratory we've been studying cell replacement therapy.

The health of the gastrointestinal system is reliant on a continual cycle of cell replacement.

The goal was to generate functional beta - like cells from pancreatic alpha cells, which may be the ideal source for beta cell replacement.

Cell replacement therapies require clinically safe stem cells that can be used to generate many (possibly all) types of cells.

San Diego, May 22, 2017 — ViaCyte, Inc., a privately - held leading regenerative medicine company, announced today that the U.S. Food and Drug Administration (FDA) has allowed the company's Investigational New Drug Application (IND) for the PEC - Direct ™ product candidate, a novel islet cell replacement therapy in development as a potential cure for patients with type 1 diabetes who are at high risk for acute life - threatening complications.

«These events offer several venues and platforms to share the exciting progress ViaCyte is making in developing novel cell replacement therapies for diabetes,» said Paul Laikind, PhD, President and CEO of ViaCyte.

JDRF and ViaCyte share a continuing commitment to realizing the potential of beta cell replacement strategies to deliver insulin independence without immune suppression for people living with type 1 diabetes, and ultimately, at JDRF we hope this will move us forward in fulfilling our vision of a world without type 1 diabetes.»

Recognizing there is still a tremendous need for better diabetes treatments, ViaCyte remains dedicated to developing cell replacement technologies as a way to significantly improve patients» lives.»

In 2017, ViaCyte, Inc. announced the allowance of clinical testing for its PEC - Direct cell replacement product candidate for high - risk type 1 diabetes.

Our group is specifically working on improvement of islet isolation and transplantation protocols in clinical practice and the development of novel therapeutic options in the field of beta cell replacement with a clear translational «bench to bedside» approach by linking experimental research with preclinical and clinical work:

Various cell types have been examined for use in RPE cell replacement including immortalized cell lines, such as the human RPE cell line, ARPE19 [2], sheets of adult RPE [3], foetal RPE [4], RPE derived from human embryonic stem cells (HESC - RPE)[5]--[10] and many non-RPE cells lines [11]--[15].

This has potential applications for cell replacement without the immunosuppression treatments that are required when cells are transferred between genetically different individuals.

The findings reveal that NG2 glia represent a promising target for neuronal cell replacement strategies to treat traumatic brain injury.

«Our long term goal is to develop a personalized cell replacement therapy using a patient's own cells to treat boys with Duchenne,» said Hicks.

The notion that metformin might promote neurogenesis and brain cell replacement is a very attractive hypothesis.»

These patients have a particularly urgent unmet medical need and could benefit greatly from cell replacement therapy.»

Although traditional cell replacement remains a central goal in applied stem cell research, the derivation of patient - specific iPS cells might be equally useful for disease - related research.

Key results included: near equal numbers of autologous (46 %) and allogeneic (41 %) trials; many of the trials are in the later stages — Phase I (49 %), Phase II (40 %) or Phase III (10 %); and there are significantly larger numbers of transient cell therapies (50 %) as opposed to permanent cell replacement (5 %).

Additionally, researchers found that Smed - beta - catenin - 1 plays a role in ongoing cell replacement in planaria that have not been challenged to regenerate.

ViaCyte's VC - 01 ™ product candidate, a first - in - class cell replacement therapy for the treatment of type 1 diabetes, is currently being evaluated in a Phase 1/2 trial called STEP ONE, or Safety, Tolerability, and Efficacy of VC - 01 Combination Product in Type One Diabetes.

Ultimately, we use all this information to establish innovative culture techniques for generating unlimited neural stem cell sources for the derivation of specific types of clinically relevant neuronal or glial cells, for their use in disease modelling and drug discovery platforms, and towards refining their efficacy for future cell replacement - based therapy.

Information on the clinical testing of ViaCyte's implantable cell replacement therapies can be found at Clinicaltrials.gov.

Understanding how heart muscle cells, or cardiomyocytes, change in space improves efforts for studying disease, screening drugs and conducting cell replacement therapy for future space missions.

Our beta cell replacement platform is unique among our peers, and we are continually creating improved methods of boosting and replacing beta cells, as well as imaging them in the body to encourage long - term survival.

Try to repair the damage by triggering or enhancing the body's own repair or cell replacement mechanisms; and

The history of nuclear transfer and its potential relevance to cell replacement exemplifies the principle, so often seen in many previous Lasker Awards.

The Toshiba six - cell replacement battery currently costs $ 90, so it is not cheap, but shelling out the cash is better than buying a whole new tablet should the battery no longer hold a charge (which is bound to happen with tablets as it too often does with smartphones).

That implies that blood is leaking from its circulation or body somewhere or pooling in an organ such as the spleen (one cause of splenomegaly) and that your pet still has the capacity to produce new red blood cell replacements.

Carried out troubleshooting and repair of damaged and broken scales and weighing equipment including electronic cable repair, weigh - bar and load cell replacements and structural damage.

ViaCyte's PEC - EncapTM (also known as VC - 01TM) product candidate is the first pluripotent stem cell - derived islet cell replacement therapy for the treatment of type 1 diabetes in clinical - stage development.

«You can manipulate stem cells and propagate them in a dish, but many recipients of stem cell replacement therapies will be older individuals.

JDRF and ViaCyte Announce Support for Development of PEC - Direct Cell Replacement Therapy for Type 1 Diabetes

About ViaCyte ViaCyte is a privately - held regenerative medicine company developing novel cell replacement therapies as potential long - term diabetes treatments to reduce the risk of hypoglycemia and diabetes - related complications.

In order to overcome the limited ability of the neurons of the adult nervous system to regenerate spontaneously, cell replacement strategies employing embryonic tissue transplantation show attractive potential.

His lab is at the forefront of developing cell replacement therapies for Parkinson's disease.

Our research goal is to understand the molecular and cellular events required for pancreatic β - cell regeneration, and apply this knowledge towards the development of cell replacement therapies for diabetes.

STEP ONE is the first trial in the world investigating a stem cell - derived beta cell replacement therapy for diabetes.

The company is the first to advance an encapsulated islet cell replacement therapy for type 1 diabetes into clinical trials.

Moreover, by uncovering a hitherto unknown mechanism mediating neuronal differentiation, the study by Makeyev and co-authors should facilitate development of novel cell replacement therapies for neurological and neurodegenerative diseases.

The isolation of human embryonic stem cells by James Thomson and his colleagues in 1998 now offers the prospect of similar advances for human systems and the promise of a new modality of medicine — cell replacement therapy.

But for cell replacement therapy to realize its potential, I anticipate that scientists must solve the developmental code, the set of rules that govern the formation of tissues, organs, and beings from the original single cell — the zygote.

Nevertheless, he thinks this sort of technology will be seen in the clinic before a treatment based on a stem cell replacement for photoreceptors.